Christopher Senner Sells 30,617 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher Senner sold 30,617 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the transaction, the chief financial officer owned 976,092 shares of the company’s stock, valued at $42,625,937.64. The trade was a 3.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Exelixis Stock Performance

EXEL opened at $44.16 on Friday. The business’s 50-day simple moving average is $43.83 and its 200 day simple moving average is $41.15. Exelixis, Inc. has a 52-week low of $32.38 and a 52-week high of $49.62. The firm has a market capitalization of $11.47 billion, a PE ratio of 15.94, a PEG ratio of 1.00 and a beta of 0.42.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period last year, the company earned $0.55 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. On average, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Zacks Research upgraded shares of Exelixis from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Wells Fargo & Company raised their target price on shares of Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Weiss Ratings reiterated a “buy (b)” rating on shares of Exelixis in a report on Thursday, January 22nd. Citigroup lowered Exelixis from a “market outperform” rating to an “underperform” rating in a research note on Monday, January 5th. Finally, Morgan Stanley raised their price objective on Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $47.11.

Hedge Funds Weigh In On Exelixis

Several institutional investors and hedge funds have recently modified their holdings of the business. Farallon Capital Management LLC raised its position in shares of Exelixis by 21.6% in the third quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock valued at $805,412,000 after buying an additional 3,466,000 shares in the last quarter. AQR Capital Management LLC raised its holdings in Exelixis by 48.8% in the 4th quarter. AQR Capital Management LLC now owns 13,658,388 shares of the biotechnology company’s stock valued at $598,647,000 after acquiring an additional 4,477,029 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Exelixis by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 7,445,469 shares of the biotechnology company’s stock valued at $328,196,000 after acquiring an additional 28,289 shares during the period. Invesco Ltd. grew its holdings in shares of Exelixis by 1.6% during the 4th quarter. Invesco Ltd. now owns 6,054,743 shares of the biotechnology company’s stock worth $265,379,000 after purchasing an additional 94,218 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of Exelixis by 42.9% in the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after purchasing an additional 1,580,567 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

More Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q4 earnings beat: Exelixis reported $0.94 EPS vs. $0.74 expected and showed y/y revenue growth (Q4 revenue $598.7M), which supports earnings momentum and margin strength. MarketBeat EXEL summary
• Positive Sentiment: Institutional / analyst backdrop is broadly constructive: multiple funds have added or increased stakes and several analysts have maintained or slightly raised targets (consensus target ~ $47.11), which leaves upside if execution/clinical data remain favorable. Analyst & institutional notes
• Neutral Sentiment: Short interest note appears anomalous — the reported February short interest shows 0 shares (short‑interest ratio 0.0 days), likely a data reporting artifact and not informative for positioning. (Source: short‑interest entry)
• Neutral Sentiment: Technical / valuation context: market cap ~ $11.5B, P/E ~16, 50‑day sma ≈ $43.8 and 200‑day sma ≈ $41 — the stock sits between short‑ and long‑term averages so momentum could swing with new catalysts. Key metrics
• Negative Sentiment: Large executive/insider selling this week: EVP Patrick Haley sold 67,814 shares (~$2.95M on Feb 17). Such large insider disposals can create negative optics about timing or liquidity needs. Haley SEC filing
• Negative Sentiment: Repeated CFO sales: Christopher Senner disclosed two sales (34,278 on Feb 13 and 30,617 on Feb 17) totaling roughly $2.8M, which amplifies negative insider‑selling optics. CFO SEC filings
• Negative Sentiment: Director-level reductions: Director Bob Oliver sold 30,250 shares (~$1.33M; ~59% reduction) and other insiders (SVP Brenda Hefti, Director Sue Eckhardt) also sold smaller blocks — combined insider sales this week approximate $8–9M, which likely pressured sentiment. Oliver SEC filing Hefti SEC filing Eckhardt SEC filing

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.